The Status of ANT01 and ANeuroTech
FDA GRANTED ANT01 PHASE IIIB STUDY PROGRAM IN PARTIAL RESPONSIVE DEPRESSION (PRD). The emerging clinical late stage biopharmaceutical company ANEUROTECH have – as an outcome of the FDA Pre-IND Meeting on 19JAN2021 – reached out an agreement with the FDA to continue with its submitted Pivotal Phase IIIB development program on ANT01 in the higly… Read more »